Cempra Appoints John Bluth Executive Vice President, Investor Relations and Corporate Communications
August 01, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Second Quarter 2016 Financial Results
July 25, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., July 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
June 28, 2016 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 28, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Host Analyst and Investor Day on June 23, 2016
June 16, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 16, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
May 25, 2016 16:30 ET
|
Melinta Therapeutics, Inc.
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM) All efficacy outcome measures favored solithromycin Management to host Q&A webcast and conference call tomorrow at 8:00...
Cempra to Present Solithromycin IV Data at ATS 2016
May 12, 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 01, 2016 17:05 ET
|
Melinta Therapeutics, Inc.
NDA submissions completed for solithromycin intravenous and oral capsule formulations in the treatment of community-acquired pneumonia Management to host webcast and conference call tomorrow at...
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
May 01, 2016 17:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin is designated by FDA as a Qualified Infectious Disease Product FDA has granted Priority Review and Fast Track designation for solithromycin IV and capsules for the treatment of CABP ...
Cempra to Report First Quarter 2016 Financial Results
April 25, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
April 06, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...